Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Filament Health Corp N.FH

Alternate Symbol(s):  FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral... see more

Recent & Breaking News (NEO:FH)

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS BOTANICAL PSILOCYBIN DRUG CANDIDATE PEX010

Canada NewsWire August 8, 2023

FILAMENT HEALTH ANNOUNCES UPSIZING AND CLOSING OF $2,500,000 NON-BROKERED PRIVATE PLACEMENT FINANCING

Canada NewsWire July 24, 2023

FILAMENT HEALTH CORP. ANNOUNCES NON-BROKERED PRIVATE PLACEMENT UNIT OFFERING OF UP TO C$2,000,000

Canada NewsWire July 19, 2023

FILAMENT HEALTH CORP. TO LIST ON NASDAQ THROUGH BUSINESS COMBINATION WITH JUPITER ACQUISITION CORPORATION

Canada NewsWire July 19, 2023

FILAMENT HEALTH ANNOUNCES CHANGE OF AUDITOR

Canada NewsWire July 14, 2023

FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES OF HEALTH RESEARCH PSILOCYBIN OPERATING GRANTS

Canada NewsWire July 6, 2023

Filament Health enters exclusive licensing deal with NeoLumina

Brieanna McCutcheon  June 30, 2023

FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC.

Canada NewsWire June 30, 2023

FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO

Canada NewsWire May 30, 2023

FILAMENT HEALTH ANNOUNCES FIRST EVER NAGOYA PROTOCOL-COMPLIANT SHIPMENT OF IBOGA FROM GABON

Canada NewsWire May 17, 2023

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire May 12, 2023

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

Canada NewsWire May 8, 2023

FILAMENT HEALTH ANNOUNCES SPRING 2023 EVENT AND MEDIA APPEARANCES

Canada NewsWire April 25, 2023

PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules

GlobeNewswire April 11, 2023

FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES

Canada NewsWire April 11, 2023

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire March 31, 2023

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING PSILOCYBIN FOR METHAMPHETAMINE USE DISORDER

Canada NewsWire March 15, 2023

FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH

Canada NewsWire February 14, 2023

Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences

Accesswire January 23, 2023

FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN

Canada NewsWire January 18, 2023